Bacterial extracellular vesicles
Provided herein are methods and compositions related to EVs useful as therapeutic agents.
1. A method of treating an immune disorder in a subject comprising administering to the subject a pharmaceutical composition comprising isolated bacterial extracellular vesicles (EVs), wherein at least 90% of the total EV and bacteria particles in the pharmaceutical composition are EVs from Prevotella or Veillonella bacteria.
2. The method of claim 1 , wherein the pharmaceutical composition is administered orally.
3. The method of claim 1 , wherein the subject is a human.
4. The method of claim 1 , wherein the pharmaceutical composition is formulated as a capsule or tablet.
5. The method of claim 1 , wherein the immune disorder is psoriasis or atopic dermatitis.
6. The method of claim 1 , wherein the pharmaceutical composition comprises at least 1×10 6 isolated bacterial extracellular vesicles (EVs).
7. The method of claim 1 , wherein at least 95% of the total EV and bacteria particles in the pharmaceutical composition are EVs.
8. The method of claim 1 , wherein no more than 1% of the total EV and bacteria particles in the pharmaceutical composition are bacteria.
9. The method of claim 1 , wherein at least 95% of the total protein in the pharmaceutical composition is present in EVs.
10. The method of claim 1 , wherein no more than 1% of the total protein in the pharmaceutical composition is present in bacteria.
11. The method of claim 1 , wherein at least 95% of the total lipids in the pharmaceutical composition is present in EVs.
12. The method of claim 1 , wherein no more than 1% of the total lipids in the pharmaceutical composition is present in bacteria.
13. The method of claim 1 , wherein the pharmaceutical composition is free of bacteria.
14. The method of claim 1 , wherein the pharmaceutical composition comprises at least 5×10 6 isolated EVs.
15. The method of claim 1 , wherein the EVs are from a single strain of bacteria.
16. The method of claim 1 , wherein the EVs are from Prevotella histicola bacteria.
17. The method of claim 1 , wherein the EVs are from Veillonella tobetsuensis bacteria or Veillonella parvula bacteria.
18. A method of treating psoriasis or atopic dermatitis in a subject comprising orally administering to the subject a pharmaceutical composition comprising isolated bacterial extracellular vesicles (EVs), wherein at least 90% of the total EV and bacteria particles in the pharmaceutical compositions are EVs from Prevotella histicola bacteria.
19. A method of treating psoriasis or atopic dermatitis in a subject comprising orally administering to the subject a pharmaceutical composition comprising isolated bacterial extracellular vesicles (EVs), wherein at least 90% of the total EV and bacteria particles in the pharmaceutical compositions are EVs from Veillonella tobetsuensis bacteria or Veillonella parvula bacteria.